Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × fosbretabulin × Clear all

Phase

Phase 2 5 Phase 1 4 Phase 1/2 2 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Endocrine 1

Conditions

Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1

Interventions

Cisplatin 81 Fluorouracil 55 Gemcitabine 53 Docetaxel 52 Paclitaxel 51 Oxaliplatin 51 Cyclophosphamide 51 Carboplatin 50 Capecitabine 49 Radiotherapy 43 Drug Therapy 42 pembrolizumab 33 Leucovorin 31 Bevacizumab 31 Doxorubicin 29 Magnetic Resonance Spectroscopy 25 Dexamethasone 25 Cytarabine 24 Etoposide 23 Nivolumab 22 Pemetrexed 21 Methotrexate 21 Radiation 17 Vincristine 16 apatinib 15 Prednisone 15 Irinotecan 15 Epirubicin 15 venetoclax 14 Trastuzumab 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00507429 2014-06-09

FACT

Mateon Therapeutics

Phase 2/3 Terminated

80 enrolled 10 charts

EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡